Combination Chemotherapy with Docetaxel and Irinotecan in Metastatic Malignant Melanoma
- 1 May 2003
- journal article
- clinical trial
- Published by Elsevier BV in Clinical Oncology
- Vol. 15 (3), 132-135
- https://doi.org/10.1053/clon.2003.0205
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2000
- Phase I and Pharmacologic Study of Docetaxel and Irinotecan in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2000
- Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical ActivityJournal of Clinical Oncology, 2000
- Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell LinesJNCI Journal of the National Cancer Institute, 1996
- Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.Journal of Clinical Oncology, 1995
- Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials groupEuropean Journal Of Cancer, 1994
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI Journal of the National Cancer Institute, 1994